Spleen Tyrosine Kinase (Syk)

Cevidoplenib (SKI-O-703) is an orally active and selective spleen tyrosine kinase (Syk) inhibitor.

Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities.

Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP).

GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1.

ER-27319, an acridone derivative, is a potent and selective SYK inhibitor, and inhibits the tyrosine phosphorylation of SYK and its activity.

PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis.

As48 is a selective TREM2 agonist with a K D value of 12.48 μM in TRIC binding assay.

PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC 50 of 3 nM.

MRL-SYKi is a chemical probe for gain-of-function variants of spleen tyrosine kinase ( SYK ).

E8431 is a DCSTAMP antagonist with an IC 50 value of 775.8 nM for osteoclastogenesis.

Piceatannol (3,3′,4,5′-trans-trihydroxystilbene) is a naturally occurring hydroxylated analogue of resveratrol.

Fostamatinib (R788) is the oral prodrug of the active compound R406, a relatively selective small molecule inhibitor of Syk .